Wendy Pang, M.D., Ph.D.

SVP Research and Translational Medicine at Jasper Therapeutics

Speaker

Dr. Pang joined Jasper with the Series A funding and has led early research and development, playing a pivotal role in advancing briquilimab across multiple clinical indications and studies in both mast cell- and blood stem cell-related diseases. Prior to Jasper, Dr. Pang was an Instructor in the Division of Blood and Marrow Transplantation at Stanford University, where she had an active clinical practice and conducted translational research in hematology / oncology, immunology, and stem cell biology.

She authored numerous publications on the identification and characterization of hematopoietic stem and progenitor cell behavior in aging, non-malignant hematopoietic and immune diseases, as well as hematopoietic malignancies, including MDS and acute myeloid leukemia (AML). Dr. Pang has multiple patents and patent applications. Dr. Pang completed her internal medicine residency and hematology fellowship at Stanford University. Dr. Pang holds an MD and PhD in Cancer Biology from Stanford University, and master’s and bachelor’s degrees in Biology from Harvard University.